市場調査レポート - 231632

米国における腫瘍マーカー検査市場の見通し

2015 Strategies in the US Tumor Marker Testing Market

発行 Venture Planning Group
出版日 ページ情報 英文 620 Pages
価格
Back to Top
米国における腫瘍マーカー検査市場の見通し 2015 Strategies in the US Tumor Marker Testing Market
出版日: ページ情報: 英文 620 Pages
概要

当レポートは、米国の腫瘍マーカー検査市場について、経済情勢、規制、人口動態、社会および技術動向が今後10年間に市場に与える影響とともに、病院、研究所、医療機関で利用されている40以上にわたる腫瘍マーカーの売上予測、半自動/自動分析器の設置、インストールベースなどを分析しまとめており、主要企業のプロファイルも織り込んで、概略下記の内容でお届けいたします。

イントロダクション

世界市場と技術概要

  • 癌の統計および病因
    • 乳癌
    • 肺癌
    • 結腸および直腸癌
    • 前立腺癌
    • 胃癌
    • 白血病
    • リンパ癌
    • 口腔癌
    • 皮膚癌
    • 子宮癌
    • 卵巣癌
    • 膀胱癌
  • 主な現在および新興の癌診断検査
    • イントロダクション
    • 腫瘍マーカーの分類
    • ACTH
    • アルファフェトプロテイン(AFP)
    • β2ミクログロブリン
    • CA 15-3/27.29
    • CA 19-9
    • CA-125
    • カルシトニン
    • 癌胎児性抗原(CEA)
    • エストロゲンおよびプロゲステロン受容体
    • フェリチン
    • ガストリン
    • ヒト絨毛性ゴナドトロピン(HCG)
    • インスリン
    • NSE
    • 潜血
    • パップスメア/HPV
    • 前立腺酸性フォスファターゼ(PAP)
    • 前立腺特異抗原(PSA)
    • 扁平上皮癌関連抗原(SCC)
    • TおよびBリンパ球
    • TdT
    • サイログロブリン
    • 組織ポリペプチド抗原(TPA)
    • 生化学腫瘍マーカー
    • 腫瘍遺伝子
    • ポリペプチド増殖因子
    • 異所性ホルモン
    • コロニー刺激因子
    • リンフォカイン
    • 免疫組織化学染色
    • 新興の腫瘍マーカー
  • 装置レビューと市場のニーズ
  • 現行および新興の技術
    • モノクローナルおよびポリクローナル抗体
    • 免疫測定
    • 分子診断
    • 染色体分析
    • 人工知能
    • フローサイトメトリー
    • 二次元ゲル電気泳動(2-DGE)
    • バイオセンサー
    • 競合/補完技術
  • 個別検査

米国市場

  • エグゼクティブサマリー
  • ビジネス環境
    • 医療費
    • コスト意識
    • 償還
    • 業界再編
    • マネージドケア
    • 病院
    • 承認
    • 在院日数
    • 産業多角化
    • 医師統計
    • 人口の高齢化
    • ラボラトリーにおける規制
  • 市場構造
  • 市場規模・成長・主要サプライヤーの販売、機器の設置、市場シェア

主な製品開発の機会

  • 試薬キットおよびテストシステム/パネル
  • 装置
  • コンピューター、ソフトウェア、自動化
  • 補助製品

分散検査製品設計の基準

代替的市場浸透戦略

  • 社内開発
  • 提携契約
  • 大学との提携
  • 流通戦略

市場参入障壁とリスク

  • 市場の成熟
  • 費用抑制
  • 競合
  • 技術力と限界
  • 特許の保護
  • 規制の制限
  • 分散検査市場の課題

競合のプロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Highlights

  • Comprehensive 620-page analysis of the US tumor marker testing market.
  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

  • 1. Brest Cancer
  • 2. Lung Cancer
  • 3. Colon and Rectum Cancer
  • 4. Prostate Cancer
  • 5. Stomach Cancer
  • 6. Leukemia
  • 7. Lymphoma
  • 8. Oral Cancer
  • 9. Skin Cancer
  • 10. Uterine Cancer
  • 11. Ovarian Cancer
  • 12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

  • 1. Introduction
  • 2. Tumor Marker Classification
  • 3. ACTH
  • 4. Alpha-Fetoprotein (AFP)
  • 5. Beta-2 Microglobulin
  • 6. CA 15-3/27.29
  • 7. CA 19-9
  • 8. CA-125
  • 9. Calcitonin
  • 10. Carcinoembrionic Antigen (CEA)
  • 11. Estrogen and Progesterone Receptors
  • 12. Ferritin
  • 13. Gastrin
  • 14. Human Chorionic Gonadotropin (HCG)
  • 15. Insulin
  • 16. NSE
  • 17. Occult Blood
  • 18. PAP Smear/HPV
  • 19. Prostatic Acid Phosphatase (PAP)
  • 20. Prostate-Specific Antigen (PSA)
  • 21. Squamous Cell Carcinoma Antigen (SCC)
  • 22. T and B Lymphocytes
  • 23. TdT
  • 24. Thyroglobulin
  • 25. Tissue Polypeptide Antigen (TPA)
  • 26. Biochemical Tumor Markers
    • ADA
    • B-Protein
    • PNP
    • 5'-Nucleotidase
  • 27. Oncogenes
    • Abl/abl-bcr
    • AIB1
    • BCL-2
    • BRCA1
    • CD44
    • C-fos
    • C-myb
    • C-myc
    • CYP-17
    • Erb-B
    • HPC1
    • N-myc
    • P40
    • P51
    • P53
    • PIK3CA
    • PTI-1
    • Ras
    • Reg
    • Sis
    • Src
  • 28. Polypeptide Growth Factors
  • Basic Fibroblast Growth Factor
    • Beta-TGF
    • Cachectin (TNT)
    • Calmodulin
    • ECFR
    • Nerve Growth Factor (NGF)
    • Epidermal Growth Factor (EGF)
    • Ornithine Decarboxylase
    • Transferrin
    • Transforming Growth Factor-Alpha
  • 29. Ectopic Hormones
  • 30. Colony Stimulating Factors
  • 31. Lymphokines
    • Alpha-Interferon
    • B Cell Growth Factors
    • B Cell Growth Factor (BCGF)
    • Gamma-Interferon
    • Interleukin-1 (IL-1)
    • Macrophage Activating Factor
  • 32. Immunohistochemical Stains
  • 33. Emerging Tumor Markers
    • N-Acetylglucosamine
    • Actin
    • Alpha-Actin
    • Antineuronal Antibodies
    • 7B2
    • B72.3
    • Bax
    • BCD-F9
    • BLCA-4
    • Blood Group Antigens A,B,H
    • CA 50
    • CA 72-4/TAG-72
    • CA 195
    • CA-242
    • CA-549
    • CAM 26
    • CAR-3
    • Cathepsin-D
    • Chromogranin A and B
    • Cluster 1 Antigen
    • Cluster-5/5A Antigen
    • CTA
    • CU18
    • DR-70
    • DU-PAN-2
    • Endometrial Bleeding Associated Factor
    • Endostatin
    • Epithelial Membrane Antigen
    • Feulgen Hydrolysis
    • Fibronectin
    • FSH
    • (1->3)-L-fucosyltransferase
    • Gastrin-Releasing Peptide (GRP)
    • GDCFP-15
    • Glucagon
    • Glycoamines
    • H23
    • Her-2
    • Human Carcinoma Antigen
    • HPA
    • HSP27
    • Intermediate Filaments
    • Cytokeratins/CK18/Cyfra 21-1
    • Desmin
    • Gliofibrillary Acid Protein
    • Neurofilaments
    • Vimentin
    • KA 93
    • Kinases
    • KP16D3
    • LAI
    • Leukocyte Common Antigen
    • Lewis Antigens
    • Lysophosphatidic Acid (LPA)
    • Ma 695/Ma 552
    • MABDF3
    • MAG
    • ME1
    • Minactivin
    • MN/CA9
    • MSA
    • Mucin Cancer Antigen (MCA)
    • Multiple Tumor Suppressor 1
    • Myosin
    • NEA-130
    • NMP22
    • OA-519
    • Opiod Peptides
    • P-glycoprotein
    • Pancreatic Oncofetal Antigen (POA)
    • Placental Lactogen
    • PR92
    • Proliferative Index, Ki-67
    • Px
    • RB Inactivation/Deletion
    • Ret
    • SCCL 175
    • Selectin
    • Sialic Acid
    • Sialyl SSEA-1/SLX
    • SN10
    • Somatostatin
    • TA-90
    • TABA
    • Tachykinin
    • TAG 12
    • TPS
    • Troponin
    • Tubulin
    • VCAM
    • VEGF
    • Villen

C. Instrumentation Review And Market Needs

  • 1. Abbott AxSYM
  • 2. Abbott Architect c4000
  • 3. Abbott Architect i2000 Series
  • 4. Abbott Architect ci8200 System
  • 5. Beckman Coulter UniCel Series
  • 6. Beckman Coulter Access
  • 7. Binding Site ESP600
  • 8. bioMerieux Mini Vidas
  • 9. Carolina Chemistries BioLis 24i
  • 10. DiaSorin Liaison
  • 11. Horiba ABX Pentra 400
  • 12. Inverness DS2
  • 13. J&J Vitros ECi/ECiQ
  • 14. J&J Vitros 3600
  • 15. J&J Vitros 5600
  • 16. Olympus AU5400
  • 17. Olympus AU3000i
  • 18. Olympus AU2700
  • 19. Roche Modular Analytics
  • 20. Roche Cobas Integra 400
  • 21. Roche Cobas Integra 400 Plus
  • 22. Roche Elecsys
  • 23. Roche Cobas c311
  • 24. Siemens ADVIA Centaur
  • 25. Siemens Dimension
  • 26. Siemens Dimension RxL Max
  • 27. Siemens Dimension Vista 500
  • 28. Siemens Immulite
  • 29. Siemens Stratus
  • 30. Tosoh AIA-Series
  • 31. Vital Diagnostics ATAC 8000
  • 32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

  • 1. Monoclonal and Polyclonal Antibodies
  • 2. Immunoassays
    • a. Technological Principle
    • b. Radioimmunoassay (RIA)
    • c. Enzyme Immunoassays (EIA)
      • Overview
      • ELISA
      • Immunofiltration
      • Particle-Membrane Capture Immunoassay
      • Enzyme Amplification
    • d. Fluorescent Immunoassays
    • e. Luminescence
      • Chemiluminescence
      • Bioluminescence
    • f. Latex Agglutination
    • g. Immunoprecipitation
    • H. Affinity Chromatographu
    • e. Liposome Flow-Injection Immunoassay
  • 3. Molecular Diagnostics
    • a. Technology Overview
    • b. Amplification Methods
      • PCR
      • DAP-PCR
      • Immuno-PCR
      • QC-PCR
      • CAR
      • DNA
      • HPA
      • LCR
      • NASBA
      • QBR
      • SDA
      • 3 SR, and others
  • 4. Chromosome Analysis
    • a. Chronic Myelogenous Leukemia (CML)
    • b. Acute Myeloid Leukemia (AML)
    • c. Acute Lymphoblastic Leukemia (ALL)
    • d. Malignant Lymphomas
    • Lymphoid Malignancies
    • e. Chronic Lymphocytic Leukemia (CLL)
    • f. Solid Cancers
    • g. Chromosomal Translocation and Oncogenes
  • 5. Artificial Intelligence
  • 6. Flow Cytometry
  • 7. Two Dimensional Gel Electrophoresis (2-DGE)
  • 8. Biosensors
  • 9. Competing/Complementing Technologies
    • a. CT
    • b. MRI
    • c. NMR
    • d. PET
    • e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

  • A. Executive Summary
  • B. Business Environment
  • 1. Health Care Expenditures
  • 2. Cost Consciousness
  • 3. Industry Consolidation
  • 4. Managed Care
  • 5. Hospitals
  • 6. Admissions
  • 7. Length of Stay
  • 8. Industry Diversification
  • 9. Physician Demographics
  • 10. Population Aging
    • a. Chronic Illness
    • b. Disease Incidence
    • c. Susceptibility to Iatrogenesis
    • d. Multiple Illness Cases
  • 11. Laboratory Regulations

C. Market Structure

  • 1. Centralized Testing
    • a. Hospitals
    • b. Commercial/Private Laboratories
  • 2. POT/Decentralized Testing
    • a. Physician Offices/Group Practices
    • b. Cancer Clinics
    • c. Point-Of-Care Testing
    • d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

Competitive Profiles

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

Appendixes

  • Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
  • Appendix II: Assumed Currency Exchange Rates

List of Tables

  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications In Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
  • Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by Market Segment
  • U.S., Estimated New Cancer Cases and Deaths
  • U.S., Estimated Cancer Death Rates Per 100,000 Population
  • U.S., Laboratories Performing Tumor Marker Tests by Market Segment
  • U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
  • U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume
  • U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size
  • U.S., Total Tumor Marker Test Volume Forecast by Market Segment-201
  • U.S., All Market Segments Major Tumor Marker Test Volume Forecast
  • U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
  • U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
  • U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
  • U.S., Total Tumor Marker Sales Forecast by Market Segment
  • U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
  • U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
  • U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
  • U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
  • U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Beta-2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market Segment
  • U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., CEA Test Volume and Diagnostics Sales by Market Segment
  • U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Colon-specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
  • U.S., Total Tumor Marker Sales By Major Supplier
  • U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
  • U.S., AFP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CEA Testing Market Diagnostics Sales by Major Supplier
  • U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
  • U.S., HCG Testing Market Diagnostics Sales by Major Supplier
  • U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
  • U.S., PAP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
  • U.S., PSA Testing Market Diagnostics Sales by Major Supplier
Back to Top